Voyager Therapeutics Appoints New CMO and CDO, Burns Departs
Ticker: VYGR · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1640266
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Voyager shakes up leadership: Batson is new CMO, Sell is CDO, Burns out.
AI Summary
Voyager Therapeutics, Inc. announced on June 11, 2024, the appointment of Dr. Todd M. Batson as Chief Medical Officer and Dr. Sarah L. Sell as Chief Development Officer. The company also reported the departure of Dr. James C. Burns from his role as Chief Medical Officer. These changes are effective immediately.
Why It Matters
The appointment of new key executives in medical and development roles suggests a strategic shift or expansion in Voyager's research and development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in medical and development, can indicate shifts in strategy or potential challenges that may impact the company's future performance.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- Dr. Todd M. Batson (person) — Appointed Chief Medical Officer
- Dr. Sarah L. Sell (person) — Appointed Chief Development Officer
- Dr. James C. Burns (person) — Departed Chief Medical Officer
- June 11, 2024 (date) — Effective date of appointments and departure
FAQ
Who has been appointed as the new Chief Medical Officer at Voyager Therapeutics?
Dr. Todd M. Batson has been appointed as the new Chief Medical Officer.
What is the effective date of the executive changes?
The changes are effective as of June 11, 2024.
Who has departed from their role as Chief Medical Officer?
Dr. James C. Burns has departed from his role as Chief Medical Officer.
What new role has Dr. Sarah L. Sell taken on?
Dr. Sarah L. Sell has been appointed as Chief Development Officer.
What is the principal executive office address for Voyager Therapeutics?
The principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts, 02421.
Filing Stats: 1,313 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-06-13 07:06:00
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
- $480,000 — led to receive an annual base salary of $480,000. He is also eligible to receive an annu
Filing Documents
- tm2417027d1_8k.htm (8-K) — 34KB
- tm2417027d1_ex10-1.htm (EX-10.1) — 84KB
- 0001104659-24-071048.txt ( ) — 310KB
- vygr-20240611.xsd (EX-101.SCH) — 3KB
- vygr-20240611_lab.xml (EX-101.LAB) — 33KB
- vygr-20240611_pre.xml (EX-101.PRE) — 22KB
- tm2417027d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Nathan Jorgensen, Ph.D., M.B.A. as Chief Financial Officer On June 11, 2024, Voyager Therapeutics, Inc. (the "Company") and Nathan Jorgensen entered into an employment agreement (the "Jorgensen Agreement"), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024 (the "Jorgensen Commencement Date"). On June 5, 2024, the board of directors of the Company (the "Board") authorized and approved the appointment of Dr. Jorgensen as Chief Financial Officer, principal financial officer, and principal accounting officer of the Company, effective upon the Jorgensen Commencement Date, and the compensation committee of the Board (the "Compensation Committee") authorized and approved the compensation arrangements for Dr. Jorgensen. Robin Swartz will continue to serve as the Company's Chief Operating Officer. Dr. Jorgensen, age 47, previously served as Chief Financial Officer of Vor Biopharma Inc., a biotechnology company, from May 2020 to June 2024. Prior to joining Vor Biopharma, Dr. Jorgensen served as Healthcare Portfolio Senior Manager for the Qatar Investment Authority from August 2016 to April 2020. Previously, Dr. Jorgensen served as Senior Research Analyst at Calamos Investments LLC, Associate Research Analyst at Stifel, Nicolaus & Company, Incorporated, and Competitive Intelligence Senior Analyst at Prescient Healthcare Group. Prior to entering the financial sector, Dr. Jorgensen investigated the pathobiology of Parkinson's disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his Ph.D. in neuroscience from the University of Minnesota, his M.B.A. from the Cornell SC Johnson College of Business, and his B.A. from St. John's University. Dr. Jorgensen has no
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Employment Agreement, by and between Voyager Therapeutics, Inc. and Nathan Jorgensen, Ph.D., M.B.A., effective as of July 8, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 13 , 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer)